Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).

Literature DB >> 6840176

Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).

H Ehrsson, I Wallin, S O Nilsson, B Johansson.

Abstract

The pharmacokinetics of chlorambucil has been investigated in a cross over study after oral administration of the free drug (10 mg) and its prednisolone ester (prednimustine, 100 mg). The bioavailability of chlorambucil was about five times lower when given as prednimustine as compared to administration of the free drug. The peak plasma concentration was about twice as high and it was obtained more rapidly when the free drug was given. No intact prednimustine could be detected in plasma.

Entities: Chemical Species

Mesh：

Substances：

Year: 1983 PMID： 6840176 DOI： 10.1007/bf00613827

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

10 in total

Review 1. Extramicrosomal drug metabolism.

Authors: J Pütter
Journal: Eur J Drug Metab Pharmacokinet Date: 1979 Impact factor: 2.441

2. Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma.

Authors: I Könyves; B Nordenskjöld; G P Forshell; A de Schryver; H Westerberg-Larsson
Journal: Eur J Cancer Date: 1975-12 Impact factor: 9.162

3. Effect of food on kinetics of 8-methoxsalen.

Authors: H Ehrsson; S O Nilsson; M Ehrnebo; I Wallin; G Wennersten
Journal: Clin Pharmacol Ther Date: 1979-02 Impact factor: 6.875

4. Mass fragmentographic determination of prednimustine and chlorambucil in plasma.

Authors: T Jakhammer; A Olsson; L Svensson
Journal: Acta Pharm Suec Date: 1977

5. Some metabolic aspects of a nitrogen mustard of prednisolone.

Authors: R Y Kirdani; G P Murphy; A A Sandberg
Journal: Oncology Date: 1978 Impact factor: 2.935

6. Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma.

Authors: J E Johnsson; C Tropé; W Mattsson; H Grundsell; K Aspegren; I Könyves
Journal: Cancer Treat Rep Date: 1979-03

7. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.

Authors: J Pedersen-Bjergaard; M M Hansen; C H Geisler; N I Nissen
Journal: Acta Med Scand Date: 1980

8. Pivampicillin and ampicillin in bile, portal and peripheral blood.

Authors: B Lund; J P Kampmann; F Lindahl; J M Hasen
Journal: Clin Pharmacol Ther Date: 1976-05 Impact factor: 6.875

9. Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer.

Authors: H T Mouridsen; D Kristensen; J H Nielsen; P Dombernowsky
Journal: Cancer Date: 1980-07-15 Impact factor: 6.860

10. Determination of chlorambucil in plasma by GLC with selected-ion monitoring.

Authors: H Ehrsson; S Eksborg; I Wallin; Y Mårde; B Joansson
Journal: J Pharm Sci Date: 1980-06 Impact factor: 3.534

10 in total

1. Inter- and intraindividual differences in oral chlorambucil pharmacokinetics.

Authors: P Hartvig; B Simonsson; G Oberg; I Wallin; H Ehrsson
Journal: Eur J Clin Pharmacol Date: 1988 Impact factor: 2.953

2. Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.

Authors: M M Oppitz; E Musch; M Malek; H P Rüb; G E von Unruh; U Loos; B Mühlenbruch
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

10. In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs.

Authors: Michael J Reese; Deborah W Knapp; Kimberly M Anderson; Julie A Mund; Jamie Case; David R Jones; Rebecca A Packer
Journal: PLoS One Date: 2018-09-07 Impact factor: 3.240

10 in total

Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031).

Review 1. Extramicrosomal drug metabolism.

2. Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma.

3. Effect of food on kinetics of 8-methoxsalen.

4. Mass fragmentographic determination of prednimustine and chlorambucil in plasma.

5. Some metabolic aspects of a nitrogen mustard of prednisolone.

6. Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma.

7. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.

8. Pivampicillin and ampicillin in bile, portal and peripheral blood.

9. Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer.

10. Determination of chlorambucil in plasma by GLC with selected-ion monitoring.

1. Inter- and intraindividual differences in oral chlorambucil pharmacokinetics.

2. Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.

3. On the clinical pharmacology of prednimustine.

4. The clinical pharmacology of chlorambucil and prednimustine.

Review 5. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

6. [Clinical relevance of glucocorticoid receptors in the treatment of lymphoid neoplasias].

7. Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

8. Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line.

9. A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.

10. In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs.